| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
63,980,000 |
| Market
Cap: |
583.50(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.22 - $11.59 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 245 |
| Guru Rank Value : 4.8 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicine medicines. Co.'s program include: YUPELRI™ (revefenacin) inhalation solution, nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease; and Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (Nezulcitinib), a lung-selective, nebulized JAK inhibitor, in clinical development for the potential treatment of hospitalized patients with acute lung injury caused by Coronavirus Disease 2019.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
1,254 |
5,114 |
22,963 |
172,089 |
| Total Sell Value |
$10,922 |
$50,468 |
$231,475 |
$1,835,193 |
| Total People Sold |
1 |
2 |
2 |
4 |
| Total Sell Transactions |
1 |
3 |
11 |
21 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Haumann Brett K |
Chief Medical Officer |
• – – |
2020-08-20 |
4 |
D |
$18.22 |
$84,650 |
D/D |
(4,646) |
307,810 |
|
- |
|
| Hindman Andrew A. |
SVP, Chief Financial Officer |
• – – |
2020-08-20 |
4 |
D |
$18.22 |
$78,765 |
D/D |
(4,323) |
123,135 |
|
- |
|
| Pitzer Kenneth R |
SVP, Prod Strat & Comm Plng |
• – – |
2020-08-20 |
4 |
D |
$18.22 |
$87,529 |
D/D |
(4,804) |
340,087 |
|
- |
|
| Brady Ann |
President, TBIL |
• – – |
2020-08-20 |
4 |
D |
$18.22 |
$41,760 |
D/D |
(2,292) |
100,579 |
|
- |
|
| Worboys Philip D |
SVP, Research & Transl Science |
• – – |
2020-08-20 |
4 |
D |
$18.22 |
$87,529 |
D/D |
(4,804) |
328,448 |
|
- |
|
| Worboys Philip D |
SVP, Research & Transl Science |
• – – |
2020-08-20 |
4 |
S |
$18.00 |
$307,854 |
D/D |
(17,103) |
333,252 |
|
4% |
|
| Sabesan Vijay |
SVP, Technical Operations |
• – – |
2020-08-20 |
4 |
D |
$18.22 |
$69,218 |
D/D |
(3,799) |
196,842 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2020-08-20 |
4 |
D |
$18.22 |
$254,096 |
D/D |
(13,946) |
1,289,115 |
|
- |
|
| Shafer Bradford J |
EVP, Gen. Counsel, Secretary |
• – – |
2020-08-20 |
4 |
D |
$18.22 |
$87,529 |
D/D |
(4,804) |
256,723 |
|
- |
|
| Graham Richard A |
SVP, DevelopmentOfficer |
• – – |
2020-08-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
114,223 |
|
-4% |
|
| Hindman Andrew A. |
SVP, Chief Financial Officer |
• – – |
2020-07-27 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
127,458 |
|
- |
|
| Pakianathan Deepika |
Director |
– • – |
2020-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,067 |
8,067 |
|
- |
|
| Worboys Philip D |
SVP, Research & Transl Science |
• – – |
2020-05-20 |
4 |
D |
$26.67 |
$128,203 |
D/D |
(4,807) |
350,355 |
|
- |
|
| Brady Ann |
President, TBIL |
• – – |
2020-05-20 |
4 |
D |
$26.67 |
$61,128 |
D/D |
(2,292) |
102,871 |
|
- |
|
| Sabesan Vijay |
SVP, Technical Operations |
• – – |
2020-05-20 |
4 |
D |
$26.67 |
$101,373 |
D/D |
(3,801) |
200,641 |
|
- |
|
| Pasqualone Frank |
SVP, Chief Comm Ops Officer |
• – – |
2020-05-20 |
4 |
D |
$26.67 |
$112,387 |
D/D |
(4,214) |
410,108 |
|
- |
|
| Pitzer Kenneth R |
SVP, Prod Strat & Comm Plng |
• – – |
2020-05-20 |
4 |
D |
$26.67 |
$128,203 |
D/D |
(4,807) |
344,891 |
|
- |
|
| Haumann Brett K |
SVP Clin Dev & Chief Med Ofc |
• – – |
2020-05-20 |
4 |
D |
$26.67 |
$112,334 |
D/D |
(4,212) |
312,456 |
|
- |
|
| Shafer Bradford J |
EVP, Gen. Counsel, Secretary |
• – – |
2020-05-20 |
4 |
D |
$26.67 |
$128,203 |
D/D |
(4,807) |
261,527 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2020-05-20 |
4 |
D |
$26.67 |
$371,940 |
D/D |
(13,946) |
1,303,061 |
|
- |
|
| Whitesides George M |
Director |
– • – |
2020-04-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,635 |
6,635 |
|
- |
|
| Molineaux Susan |
Director |
– • – |
2020-04-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,635 |
6,635 |
|
- |
|
| Oconnor Donal |
Director |
– • – |
2020-04-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,635 |
34,206 |
|
- |
|
| Young William D |
Director |
– • – |
2020-04-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,635 |
58,330 |
|
- |
|
| Smaldone Alsup Laurie |
Director |
– • – |
2020-04-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,635 |
24,982 |
|
- |
|
529 Records found
|
|
Page 8 of 22 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.02 (0.22%) 
